In both clinical practice and clinical trials, remission in leukemia is determined by morphological assessment — a person counting cancer cells in a bone marrow sample under a microscope. But more sophisticated technologies, such as flow cytometry, could help overcome many of the limitations of morphological assessments.
Flow cytometry is often used to measure depth of remission after absence of cancer cells has been established microscopically. But what happens when the morphological assessment indicates remission and the flow cytometry results suggest cancer?
Read the whole story at Pediatrics Nationwide: What Happens When Cancer Remission is in Question?